A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non–small cell lung cancer
KL Reckamp, K Krysan, JD Morrow, GL Milne… - Clinical cancer …, 2006 - AACR
Abstract Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …
Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer
KL Reckamp, M Koczywas, MC Cristea, JE Dowell… - Cancer, 2015 - Wiley Online Library
BACKGROUND Cyclooxygenase 2 (COX‐2)‐dependent signaling represents a potential
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non–small cell lung cancer patients …
Abstract Purpose: Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates antitumor
effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non–small cell …
effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non–small cell …
[HTML][HTML] A randomized, placebo-controlled, multicenter, biomarker-selected, Phase 2 study of apricoxib in combination with erlotinib in patients with advanced non …
BJ Gitlitz, E Bernstein, ES Santos, GA Otterson… - Journal of Thoracic …, 2014 - Elsevier
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non–small cell lung cancer
Abstract Purpose: Cyclooxygenase (COX)-2 up-regulation plays an important role in the
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …
Retracted: Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase‐2 in nonsmall cell lung cancer may be dependent on the EGFR …
SM Gadgeel, S Ali, PA Philip, F Ahmed… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs)
have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC) …
have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC) …
[HTML][HTML] Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and …
N Li, H Li, F Su, J Li, X Ma, P Gong - International journal of clinical …, 2015 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) mutations occur mostly in patients with lung
adenocarcinoma; such patients are also more likely to express cyclooxygenase-2 (COX-2) …
adenocarcinoma; such patients are also more likely to express cyclooxygenase-2 (COX-2) …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
M Gulyas, JSM Mattsson, A Lindgren, L Ek… - Acta …, 2018 - Taylor & Francis
Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
[HTML][HTML] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in …
SM Gadgeel, JC Ruckdeschel, EI Heath… - Journal of Thoracic …, 2007 - Elsevier
Background: Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
COX-2 inhibition and lung cancer
AB Sandler, SM Dubinett - Seminars in oncology, 2004 - Elsevier
Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung
cancer. In non-small cell lung cancer (NSCLC), COX-2 is overexpressed in most …
cancer. In non-small cell lung cancer (NSCLC), COX-2 is overexpressed in most …